Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay.

A quantitative real-time PCR assay was developed to measure the proviral load of human T-lymphotropic virus type I (HTLV-I) in peripheral blood mononuclear cells (PBMCs). The HTLV-I copy number was referred to the actual amount of cellular DNA by means of the quantitation of the albumin gene. Ten copies of HTLV-I DNA could be detected with 100% sensitivity, and the assay had a wide range of at least 5 log(10). Intra- and inter-assay reproducibility was evaluated using independent extractions of PBMCs from an HTLV-I-infected patient (coefficients of variation, 24 and 7% respectively). The performance of this TaqMan PCR assay, coupled with its high throughput, thus allows reliable routine follow-up of HTLV-I proviral load in infected patients. Preliminary results using clinical samples indicate a higher proviral load in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis than in asymptomatic carriers, and also suggest the usefulness of this quantitative measurement to assess the etiological link between HTLV-I and adult T-cell leukaemia/lymphoma-like syndromes.

[1]  F. Barin,et al.  ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS , 1985, The Lancet.

[2]  J. Lifson,et al.  Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load. , 2000, AIDS research and human retroviruses.

[3]  M. Yoshida,et al.  Frequent mutation in pX region of HTLV-1 is observed in HAM/TSP patients, but is not specifically associated with the central nervous system lesions. , 1995, Journal of neurovirology.

[4]  K. Yamaguchi,et al.  Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Hoffbrand Bi.  Beta-adrenergic blockage in congestive cardiomyopathy. , 1980 .

[6]  D. Gallahan,et al.  Absence of human T‐lymphotropic virus type I tax sequences in a population of normal blood donors in the Baltimore, MD/Washington, DC, area: results from a multicenter study , 1999, Transfusion.

[7]  R. Janssen,et al.  The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. , 1990, Journal of acquired immune deficiency syndromes.

[8]  Y. Ohtsuki,et al.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells , 1981, Nature.

[9]  S. Wain-Hobson,et al.  Clonal expansion of infected cells: a way of life for HTLV-I. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[10]  M. Essex,et al.  Human T cell leukemia virus type I (HTLV-I) molecular genotypes and disease outcome. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[11]  L. Ratner,et al.  Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. , 1998, Journal of virological methods.

[12]  Y. Itoyama,et al.  A Quantitative Polymerase Chain Reaction Study , 2004 .

[13]  H. Galeno,et al.  HTLV-I provirus in seronegative Chilean patients with tropical spastic paraparesis , 1996, The Lancet.

[14]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[15]  J. Weber,et al.  Quantification of proviral DNA load in human T-cell leukaemia virus type I infections. , 1998, Journal of virological methods.

[16]  F. Sigaux,et al.  High human T-cell lymphotropic virus type I proviral DNA load with polyclonal integration in peripheral blood mononuclear cells of French West Indian, Guianese, and African patients with tropical spastic paraparesis. , 1990, Blood.

[17]  S. Wain-Hobson,et al.  Human T lymphotropic virus (HTLV) type I and II DNA amplification in HTLV-I/II-seropositive blood donors of the French West Indies. , 1992, The Journal of infectious diseases.

[18]  W. Blattner,et al.  The epidemiology of the human T‐cell lymphotrophic virus type I and type II: etiologic role in human disease , 1991, Transfusion.

[19]  S. Sonoda,et al.  Increased replication of HTLV‐I in HTLV‐I–associated myelopathy , 1989, Annals of neurology.

[20]  S. Izumo,et al.  Analysis Of Htlv-I Proviral Load In 202 Ham/Tsp Patients And 243 Asymptomatic Htlv-I Carriers: High Proviral Load Strongly Predisposes To Ham/Tsp , 1998 .

[21]  W. Rozenbaum,et al.  Quantification of Human Immunodeficiency Virus Type 1 Proviral Load by a TaqMan Real-Time PCR Assay , 2001, Journal of Clinical Microbiology.

[22]  D. Spiegelman,et al.  Predictors of level of circulating abnormal lymphocytes among human T‐lymphotropic virus type I carriers in Japan , 1998, International journal of cancer.

[23]  A. Cimarelli,et al.  Quantification of HTLV-II proviral copies by competitive polymerase chain reaction in peripheral blood mononuclear cells of Italian injecting drug users, central Africans, and Amerindians. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[24]  T. Ikezoe,et al.  HTLV‐I‐seronegative, genome‐positive adult T‐cell leukemia: Report of a case , 1996 .

[25]  Mitsuhiro Osame,et al.  HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY , 1986, The Lancet.

[26]  W. Blattner,et al.  Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. , 1999, The Journal of infectious diseases.

[27]  A. Terano,et al.  Quantitation of HTLV‐I provirus among seropositive blood donors: Relation with antibody profile using synthetic peptides , 1993, International Journal of Cancer.

[28]  K. Livak,et al.  Real time quantitative PCR. , 1996, Genome research.

[29]  B. Bain,et al.  Prospective study of HTLV-I infection in an initially asymptomatic cohort. , 1999, Journal of acquired immune deficiency syndromes.

[30]  B. Korber,et al.  Polymerase chain reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells of patients with adult T-cell leukemia , 1991, Journal of virology.

[31]  M. Yoshida,et al.  Mutation rates in LTR of HTLV-1 in HAM/TSP patients and the carriers are similarly high to Tax/Rex-coding sequence. , 1996, Journal of neurovirology.

[32]  M. Hatanaka,et al.  Defective human T-cell leukemia virus in adult T-cell leukemia patients. , 1984, Molecular biology & medicine.

[33]  M. Kikuchi,et al.  Defective provirus form of human T-cell leukemia virus type I in adult T-cell leukemia/lymphoma: clinicopathological features. , 1991, Cancer research.

[34]  D. Zucker‐Franklin,et al.  Human T-Cell Lymphotropic Virus Type 1 Tax among American Blood Donors , 1998, Clinical Diagnostic Laboratory Immunology.

[35]  T. Honjo,et al.  Genomic structure of HTLV (human T‐cell leukemia virus): detection of defective genome and its amplification in MT‐2 cells. , 1984, The EMBO journal.

[36]  M. Yoshida,et al.  Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[37]  I. Bièche,et al.  TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency. , 1999, Clinical chemistry.

[38]  K. Nagata,et al.  Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Katamine,et al.  Dependency of antibody titer on provirus load in human T lymphotropic virus type I carriers: an interpretation for the minor population of seronegative carriers. , 1995, The Journal of infectious diseases.

[40]  J. D. White,et al.  Reduction in HTLV‐I proviral load and spontaneous lymphoproliferation in HTLV‐I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti‐tac , 1998, Annals of neurology.

[41]  Mitsuhiro Osame,et al.  Fluctuation of HTLV-I proviral DNA in peripheral blood mononuclear cells of HTLV-I-associated myelopathy , 1993, Journal of Neuroimmunology.